Form 4: Eterna Therapeutics Inc. Executive Sandra Gurrola Reports Stock Transactions
SEC Form 4 Filing
Sandra Gurrola, Sr. VP of Finance at Eterna Therapeutics Inc., reports the vesting and subsequent disposal of shares related to restricted stock units.
Summary
- On June 21, 2024, Sandra Gurrola, Sr. VP of Finance at Eterna Therapeutics Inc., reported transactions involving the company's common stock.
- Gurrola converted 437 restricted stock units into common stock.
- She also disposed of 180 shares to cover tax obligations at a price of $1.94 per share.
- Following these transactions, Gurrola directly owns 1,185 shares of common stock and 437 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities and beneficial ownership of company stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in insider ownership.
Key Dates
| Date | Description |
|---|---|
| 06/21/2021 | Reporting person was granted 1,750 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. |
| 06/21/2024 | Date of the reported transactions: conversion of restricted stock units and disposal of shares. |
| 06/25/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.